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ABSTRACT 
 
Transposon somatic mutagenesis is a forward genetics approach that can be used 
to identify novel genetic drivers of cancer. This research has developed tools required for 
performing these transposon mutagenesis screens in zebrafish. Transgenic zebrafish lines 
were created that allow for tissue-specific and inducible expression of the transposase 
required for the Sleeping Beauty (SB) transposon system. Mutagenesis screens will be 
performed in a pRB deficient background, which gives rise to highly proliferative and 
undifferentiated tumors resembling primitive neuroectodermal tumors (PNETs). This 
could reveal cooperating genes that interact with rb1 to affect brain cancer. To this end, 
neural progenitors were targeted using the Tg(krt5:SB11) transgenic line. The ability of 
this transgenic to mobilize transposons was demonstrated in whole larvae and adult 
brains. Also, an inducible transposase source in the Tg(ubi:floxed-SB11) transgenic line 
was able to increase transposon mobilization in response to Cre injection, despite a low 
level of background expression. Other tissue-specific promoters were explored, including 
gfap and nestin, which may result in increased tumorigenesis. 
Several mutagenesis screens are currently being monitored in both wild type and 
tumor susceptible backgrounds. Common integration sites in the zebrafish genome are 
also being mapped to aid in the analysis of data from these screens by removing 
background that does not contribute to tumorigenesis. A small scale mutagenesis screen 
in a wild type background has resulted in a single fish out of ten that developed a brain 
tumor after 8 months of age. Importantly, analysis showed that transposon mobilization 
was specific to tumor tissue, demonstrating that the Tg(krt5:SB11) transgenic line can 
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target mutagenesis to specific cell types. The results of these transposon mutagenesis 
screens could lead to a better understanding of the genetics behind PNETs and open 
possibilities for new treatments. 
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CHAPTER I 
 INTRODUCTION 
 
History of Transposons 
Since the discovery of transposable elements by Barbara McClintock in the 
1940’s, transposons have revolutionized the field of genetics. Her research into the 
Activator/Dissociation (Ac/Ds) transposon system in maize was the first description of 
mutagenesis through transposition (McClintock, 1950 & 1953).Transposons are defined 
as segments of DNA that are capable of changing their location in the genome, leading to 
the popular name jumping genes. It is now known that transposons are present in almost 
every organism from prokaryotes to humans, and in many cases, make up a significant 
portion of the host genomes. Their discovery has not only led to a better understanding of 
our evolution and genetic past, but also has provided important genetic tools for research. 
 
Types of Transposons 
Transposable elements can be divided into two main groups corresponding to 
their mechanism of action (Pray, 2008). Class I transposons are known as 
retrotransposons, named for the requirement of reverse transcriptase for mobilization. 
Transposition is achieved by transcribing the transposon into an RNA intermediate. 
Reverse transcriptase, encoded by the transposon, then produces a DNA copy of the 
transposon which can be integrated back into the host genome at the target site. The result 
is the duplication of the transposon from one site to the other, while leaving the original 
transposon behind. As a result, this is referred to a copy and paste mechanism. 
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The other group of transposon fall into class II, or DNA transposons. These do not 
require a RNA intermediate, but instead rely on a transposase that recognizes and binds 
to the transposon, excises it from the donor DNA, and then inserts it at the new target 
site. In contrast to the retrotransposons, DNA transposons exhibit a cut and paste 
mechanism. Due to the sequence specificity that each transposase recognizes, different 
transposons require a certain transposase to be mobilized. 
In addition to these broad classifications, transposon can be further divided based 
on their ability to catalyze their own transposition. A transposon that encodes for the 
transposase or reverse transcriptase required for its own function is said to be 
autonomous. A non-autonomous transposon lacks this ability, and therefore requires 
other transposable elements for its mobilization. 
 
Transposons in Research 
The development of transposons has led to many research applications. In 
particular, the Tol2 and Sleeping Beauty transposon systems have had significant 
influence in research and are two transposons that will be used in this research. The Tol2 
transposase system is a well characterized method for introducing transgenes into 
organisms (Kawakami, 2007 & Ni et al, 2016). It is a class II, DNA transposon that 
requires the Tol2 transposase to catalyze transposon integration in the host genome. 
Transgenes are constructed in a Tol2 transposon flanked by inverted repeats. For 
zebrafish, this DNA construct and transposase mRNA are injected into zebrafish at one-
cell stage. Although this results in mosaic integration of the transgene in injected fish, 
transgenic lines can be recovered from their offspring. 
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Sleeping Beauty Transposon 
A good example of a transposable element being used for research purposes is the 
Sleeping Beauty transposon system. As the name implies, Sleeping Beauty (SB) was an 
inactive transposon found in the genome of a salmonid species that was engineered to 
restore its original function (Ivics et al., 1997). A putative functional transposon sequence 
was generated based on phylogenetic analysis to obtain a consensus sequence with 
conserved domains. The revived SB transposon was then synthesized by eliminating the 
deleterious mutations to match this consensus sequence. This involved restoring the open 
reading frame of the transposase and repairing mutations to the DNA binding and 
catalytic domains. The restored transposase was named SB10 and was successfully used 
to drive transposition in human cells (Ivics et al., 1997). 
The SB transposon falls into the Tc1/mariner superfamily. This family includes 
DNA transposons that are present in a wide variety of organisms. This makes SB 
advantageous for use in vertebrate research as it has a wider host range (Plasterk et al., 
1999). Structurally, the transposon contains two terminal inverted repeats flanking the SB 
transposase gene (Ivics et al, 2015). For research purposes, however, the transposase gene 
can be replaced with a gene of interest or other genetic cargo, and the transposase 
supplied through another method. This allows the SB transposon system to be used for a 
wide range of research applications (Izsvák et al., 2004). 
As a class II transposon, SB is mobilized by the cut and paste method (Walisko et 
al., 2008). Transposition begins when SB transposase binds to the inverted repeats on the 
transposon, with two units of the transposase at each end. The synaptic complex forms as 
the transposase subunits bind, bringing the two ends together, resulting in DNA cleavage. 
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Finally, the transposon is excised from the donor site and is introduced at a new target 
site. The resulting double stranded break in the donor DNA is repaired by non-
homologous end joining. One of the advantages of the SB system is that the target site 
requirements for transposition have few restrictions, only requiring a TA dinucleotide. 
These qualities of have made the SB transposon an important tool in research. 
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CHAPTER II 
TRANSPOSON SOMATIC MUTAGENESIS 
 
Background 
The use of transposon insertional mutagenesis is valuable for forward genetic 
screens. This kind of approach is important as it reveals new targets for cancer research to 
pursue (Mann et al., 2014). Several studies have been done in mice using the SB11 
transposon system to identify cancer genes through the disruption of random genes 
throughout the genome (Collier et al, 2005, Dupuy et al, 2005, Moriarity et al., 2015), 
and the system has been used in zebrafish by our lab (McGrail et al., 2011). Zebrafish 
offer several advantages as a vertebrate model organism for forward genetic screens. 
They have a short generation time and high fecundity, resulting in great numbers of 
individuals in a relatively short amount of time. Their genome has been sequenced and a 
number of genetic tools have been developed for their use, including transposons for 
generating transgenics and genome editing techniques. The ability to study specific genes 
and their role in cancer has improved dramatically since the utilization of TALENs and 
CRISPRs. However, forward genetic approaches are still required to better understand 
tumorigenesis by identifying novel genes that contribute to the cancer phenotype. 
Transposon mutagenesis screens are often carried out in a tumor-susceptible 
background. This allows for the discovery of cooperating genes that interact to contribute 
to cancer. In the pRB model, in which rb1 is targeted using TALENs, adult mosaic 
mutants develop tumors that share characteristics of a type of cancer called PNETs (Solin 
et al., 2015). Primitive neural ectodermal tumors (PNETs) are a form of highly malignant 
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brain cancer that usually affects children and has a low survivability (Smoll, 2012). A 
somatic insertional mutagenesis screen in the pRB model should identify cooperating 
genes leading to the PNET phenotype.  
 The somatic insertional mutagenesis screen using the SB11 system involves two 
main components. First, a gene break transposon array is required to disrupt gene express 
after integration. Transposons such as the T2/OncZ enable the identification of both 
tumor suppressors and oncogenes through either over expression or premature 
termination. The second component is the transposase source. When SB11 transposase is 
introduced, transposon mobilization results in the random integration of the transposon 
throughout the genome. This transposase source can either be transient, such as injected 
mRNA for the protein, or expressed by the cell through transgenics. The use of promoters 
can determine if SB11 expression is constitutive or limited to specific tissues.  
In this research, a tissue-specific and inducible transposase source will be used to 
drive somatic transposon mutagenesis to identify novel genes that contribute to 
tumorigenesis. The ability to direct mutagenesis to specific cell types in an inducible 
manner is a very valuable technique in studying tumorigenesis. It would allow 
mutagenesis in the cell types of interest and their future lineages, as well as after critical 
stages of development. Neural progenitors are of particular interest for our PNET model. 
Several reports have shown that neural progenitors can be targeted through the use of the 
keratin5 (krt5) promoter. Tumorigenesis was promoted when using the krt5 promoter as a 
driver to activate the Sonic hedgehog signaling pathway (Ju et al., 2014). It was also used 
to drive overexpression of human KRAS in zebrafish, resulting in malignant brain tumors 
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(Ju et al., 2015). Therefore, this promoter will be used to drive SB11 transposase 
expression for the mutagenesis screens. 
In addition to targeting the transposon mutagenesis screen in specific tissues, it 
can also be controlled using an inducible transposase source. This will be accomplished 
using the Cre-Lox system and a tamoxifen-inducible Cre. Expression of SB11 transposase 
will be prevented until the tamoxifen is introduced. Driving the inducible Cre from a 
tissue specific promoter would allow for both the spatial and temporal control of the 
mutagenesis screen. Taking this forward genetics approach, the transposon mutagenesis 
screen should reveal novel genetic drivers of tumorigenesis and provide candidate genes 
for future study. This will help gain a better understanding of the mechanisms of 
tumorigenesis and could provide insights into possible treatments. 
 
Methods 
Cloning constructs for the expression of a transgene 
All PCR reactions described were performed with KOD master mix, following the 
manufacturer’s protocol. Primer sequences are provided in Table 1. The krt5 promoter 
was cloned from zebrafish genomic DNA. Two pairs of primers were designed for a 
nested PCR. In the first round of PCR, the target sequence was amplified with the 
surrounding 30-40 bps. The second round of PCR used the resulting product as template 
to amplify up the target sequence to obtain the krt5 promoter flanked by restriction sites. 
The restriction sites NotI and NheI were used to insert the amplified promoter into a 
vector to create pTol2<krt5:SB11, cmcl2:GFP>. The construct pTol2<gfap:SB11, 
cmlc2:GFP> was similarly made by amplifying the gfap promoter from a plasmid 
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obtained from Addgene (#39761). The pTol2<krt5:SB11, cmcl2:GFP> plasmid was 
modified to pTol2<krt5:GFP> by digesting with NheI and AgeI to remove the SB11 
coding region to the cmcl2 promoter, followed by a blunt end ligation. 
 The ubiquitin promoter used in the Tg(ubi:floxed-SB11) construct was obtained 
from Addgene (#27320). The promoter region was excised using the restriction sites 
NheI and BamHI, and inserted into a vector to create pTol2<ubi:floxed-SB11, 
cmlc2:GFP>. The termination signal consisting of two SV40 sequences surrounded by 
LoxP sites was amplified from a plasmid template. The BamHI restriction sites were used 
to insert this transcription terminator sequence between the ubiquitin promoter and SB11 
coding region to yield pTol2<ubi:floxed-SB11, cmlc2:GFP>.  The  pTol2<ubi:GFP> 
plasmid was obtained by digesting pTol2<ubi:floxed-SB11, cmlc2:GFP> with BamHI 
and AgeI to remove the floxed-SB11 and cmlc2 promoter, followed by a blunt end 
ligation. The nestin promoter was amplified from genomic DNA and cloned directly into 
the pCR-BluntII-Topo vector. This allowed the promoter to be cloned into the p5’E:MCS 
vector using the restriction sites KpnI and SacII to yield p5’E:nestin.  
 
Table 1. Primer sequences for cloning constructs. 
 
Primer Name Sequence (5’ to 3’) 
krt5-nested-forward GCTCATGCTTCCACTACTGG 
krt5-nested-reverse AGAACTGGGAAACTGAGACTG 
krt5-promoter-forward ATTAGCGGCCGCGAAAGCGACTCCACCC 
krt5-promoter-reverse ATTAGCTAGCGAGGGGGTGAGGATCAGA 
loxP-SV40-forward ATTAGGATCCTCCGGAATTCATAACTTCG 
loxP-SV40-reverse ATTAGGATCCTGCAGGATATCGATATAACTTC 
gfap-promoter-forward ATTAGCTAGCGAGGTAAGGACTGAGGTG 
gfap-promoter-reverse ATTAGCATGCGGTGGAGGAGAATGAG 
nestin-promoter-forward AGTCGGTACCAGGAAGTTTCCAGTGTTGTG 
nestin-promoter-reverse AGCTCCGCGGTCACTAGAGGCTGTGAAGAA 
 
9 
 
Generating and characterizing transgenic zebrafish lines 
Transgenics were created by co-injecting the vector containing the transgene in 
the Tol2 backbone with Tol2 transposase. For each transgenic line, 50 pg of the construct 
and 125 pg of the Tol2 mRNA was injected. Injected embryos were screened for a 
reporter gene and founders were identified. 
SB11 expression in the Tg(krt5:SB11) was analyzed using whose mount in situ 
hybridization on 2 day old larvae. The probe was the entire antisense SB11 coding region. 
The control included was the leptin b probe, which has been used previously. The ability 
of these transgenic lines to mobilize the transposon was determined using a transposon 
excision assay, in which PCR was used to amplify specific sequences along the 
transposon. Primers were previously designed to amplify across the excision site and the 
left arm of the transposon. These sequences are provided in Table 2. The Tg(ubi:floxed-
SB11) system was tested by injecting of 50 pg Cre mRNA into progeny from a cross with 
T2/OncZ. Injected and uninjected larvae were raised to 5 days of age, separated according 
to genotype, and used to extract genomic DNA. The transposon excision assay was used 
to determine if SB11 was being expressed. 
 
Table 2. Primer sequences for the transposon excision assays. 
 
 Primer Name  Sequence (5’ to 3’) 
T2/OncZ-forward ATGTGCTGCAAGGCGATTAAGTTG 
T2/OncZ-arm-reverse ATCAAGCTTCTAAAGCCATGACATC 
T2/OncZ-across-reverse TGAGCGGATAACAATTTCACACAGG 
T2/OncZgb-forward TGTAAAACGACGGCCAGT 
T2/OncZgb-arm-reverse GACCCACTGGGAATGTGATGAAAG 
T2/OncZgb-across-reverse GTCGACGGTATCGATAAGCTTG 
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Preparing sample libraries for common integration site analysis 
A cross was setup between the Tg(β-actin:SB11) transgenic and the T2/OncZgb1 
transposon line. Progeny were separated based on genotype and raised to adulthood. At 2 
months of age, the fish were sacrificed and the entire trunk of the body used for genomic 
DNA extraction. Linker mediated PCR was used to amplify insertion sites (McGrail et 
al., 2011). The libraries were constructed using the primers listed in Table 3. A total of 48 
samples were prepared for each arm of the transposon. Samples were barcoded with one 
of 24 barcoded primers, listed in Table 4. The first set of samples containing 24 libraries 
from the left transposon arm were sent for sequencing on the MiSeq with 150-cycles. 
In order to ensure that the common integration site libraries contained sequences 
of the transposon flanking genomic DNA, random clones were isolated and sequenced. 
Each sample was run on a gel and excised, purified, and used for TA cloning. This 
allowed random fragments from each sample to be cloned into the pCR4-Topo vector. 
Clones were selected and individual colonies were grown up. The plasmid DNA was sent 
for standard Sanger sequencing. 
 
Table 3. Primer sequences for common integration site library construction. 
 
Primer Name Sequence (5’ to 3’) 
NlaIII_Linker_+ GTAATACGACTCACTATAGGGCTCCGCTTAAGGGACCATG 
NlaIII_Linker_- Phos-GTCCCTTAAGCGGAGC-3’spacer 
BfaI_Linker_+ GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC 
BfaI_Linker_- Phos-TAGTCCCTTAAGCGGAGC-3’spacer 
Primary_IRR1 GCTTGTGGAAGGCTACTCGAAATGTTTGACCC 
Primary_IRL1 CTGGAATTTTCCAAGCTGTTTAAAGGCACAGTCAAC 
Primary_Linker GTAATACGACTCACTATAGGGC 
Secondary_Linker CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTAGG
GCTCCGCTTAAGGGAC 
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Table 4. Barcoded primers for common integration site 
library construction. Barcodes are shown in red. 
 
Primer Name Sequence (5’ to 3’) 
Secondary_IR-BC1 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTAGGAGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC2 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTGCGAGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC3 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTCTGAGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC4 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTAACAGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC5 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTGGCAGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC6 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTTCCAGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC7 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTGATAGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC8 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTCGTAGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC9 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTACTAGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC10 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTGAAGGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC11 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTAGAGGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC12 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTCCAGGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC13 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTATCACGTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC14 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTCGATGTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC15 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTTTAGGCTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC16 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTTGACCATGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC17 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTACAGTGTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC18 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTGCCAATTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC19 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTCAGATCTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC20 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTACTTGATGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC21 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTGATCAGTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC22 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTTAGCTTTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC23 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTGGCTACTGTATGTAAACTTCCGACTTCAACTG 
Secondary_IR-BC24 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCTCTTGTATGTATGTAAACTTCCGACTTCAACTG 
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Crosses performed for transposon mutagenesis screens 
A transposon mutagenesis screen was performed using the Tg(krt5:SB11) 
transgenic and T2/OncZ transposon line. Progeny of the cross were separated according 
to genotype. At five days of age, several larvae were used to extract genomic DNA for a 
transposon excision assay. The remaining fish were raised to adulthood. Of the double 
transgenics, one developed a tumor originating from the head. The fish was sacrificed 
and portion of the tumor and muscle was removed for extracting genomic DNA using the 
Qiagen Blood and Tissue Extraction kit. A transposon excision assay was used to show 
transposon mobilization in the tumor tissue. 
Two large scale screens were performed with the Tg(krt5:SB11) and T2/OncZgb1 
transposon line. The first was in a wild type background. Transposon mobilization in 
double transgenics was verified by dissecting adult brains and extracting genomic DNA 
that was used for the excision assay. An additional mutagenesis screen was carried out in 
the pRB deficient background by injecting TALENs for rb1 at the one-cell stage. The 
fish from both screens are still being monitored for tumorigenesis. 
 
Results 
Isolation of transgenic lines for tissue specific and inducible transposase sources 
In this research, transposon somatic mutagenesis will be used to identify genetic 
drivers that contribute to the development of the PNET phenotype. To accomplish this, 
tissue specific and inducible transposase sources were explored. The design of the 
constructs used to create these transgenic zebrafish lines is illustrated in Figure 1. The 
number of independent lines of each transgenic is summarized in Table 5. The targeting 
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of neural progenitors is of particular interest, as these cells are thought to be the origin of 
over proliferation in our model. Studies have shown that the krt5 promoter could be used 
to drive tumorigenesis in the brain by targeting neural progenitors (Ju et al., 2014). This 
promoter was therefore chosen to drive transposase expression for the mutagenesis 
screens. In total, three independent transgenic lines of Tg(krt5:SB11) were isolated. 
 
Figure 1. Transposon construction design to generate transgenics, 
including the tissue-specific and inducible expression of a transposase.  
 
Table 5. Number of independent lines of each transgenic that has been isolated. 
 
 
The ability of the Tg(krt5:SB11) transgenic line to drive transposon mobilization 
was tested with a small scale mutagenesis screen by crossing with the T2/OncZ line. 
Transposon mobilization was measured using an excision assay, which is shown in 
Figure 2. In this assay, amplification across the excision site is achieved only when the 
transposon has been mobilized. The 300 bp band observed in the double transgenics, 
individuals with both the transposon and transposase, indicates transposon excision. 
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Controls for the presence of the transposon are included, showing amplification of a 420 
bp product on the transposon arm. This confirms that the Tg(krt5:SB11) can drive 
transposon mobilization as expected. 
 
Figure 2. Excision assay of whole larvae showing mobilization 
of the T2/OncZ transposon when crossed to Tg(krt5:SB11). 
 
The large scale screens will be using the T2/OncZgb1 transposon. The 
function of the Tg(krt5:SB11) transgenic line to catalyze mobilization of the 
T2/OncZgb1 transposon was confirmed using an excision assay of dissected 
brains. The results of this assay are shown in Figure 3. As with the previous 
excision assay, the amplification across the excision site can only be after 
transposon mobilization, indicated by the red arrow. The results show that 
Tg(krt5:SB11) can be used for the large scale mutagenesis screens. 
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Figure 3. Excision assay of dissected brains showing mobilization 
of the T2/OncZgb1 transposon when crossed to Tg(krt5:SB11) 
 
The expression pattern of the Tg(krt5:SB11) transgenic was analyzed in 2 day old 
larvae using whole mount in situ hybridization. The results are shown in Figure 4. The 
results were inconclusive, as there was not an appreciable difference between the 
transgenics expressing SB11 and the wild type. The probe designed for the in situ 
consisted of the entire antisense sequence of SB11. Analyzing this sequence against the 
zebrafish genome resulted in a high level of homology. This could explain the presence 
of the probe in the wild type. In future efforts to characterize SB11 expression in the 
Tg(krt5:SB11) transgenic, an alternative probe will be used that does not map to the 
zebrafish genome. 
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Figure 4. Whole mount in situ hybridization to characterize 
the expression of SB11 transposase in Tg(krt5:SB11). 
 
Another method was explored to visualize the activity of the krt5 promoter. The 
Tg(krt5:GFP) transgenic line was isolated to observe the expression of GFP, in order to 
have some insight into the SB11 expression pattern in the Tg(krt5:SB11) line. The 
confocal image shown in Figure 5 shows intense GFP expression throughout the skin, as 
expected, as well as significant expression in the brain. Sectioning of these fish would 
provide a more detailed visualization of GFP throughout the brain. 
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Figure 5. GFP expression in the skin and brain in Tg(krt5:GFP) at 2 dpf. 
 
 In addition to tissue-specificity, and inducible transposase source would be 
advantageous for initiating transposon mutagenesis after critical stages of development. 
A common method for achieving inducible control of a transgene is the Cre-Lox system, 
which was to be used in this research. One part of this system has been developed so far. 
Three independent lines of the Tg(ubi:floxed-SB11) transgenic have been isolated. This 
transgenic line was generated in order to achieve inducible control of transposase 
expression with Cre recombinase. To test its ability to induce transposon mobilization in 
the presence of Cre, this line was crossed with the T2/OncZ line and Cre mRNA was 
injected. A transposon excision assay revealed a relatively low amount of transposon 
excision in non-injected individuals, as shown in Figure 6. In individuals injected with 
Cre mRNA, the band corresponding to transposon excision is much more intense. These 
results suggest that the transcription terminator that was meant to prevent transcription of 
the SB11 transgene is not completely effective. Therefore, a low level of SB11 expression 
is ubiquitously expressed even in the absence of Cre recombinase. Despite this leakiness, 
the presence of Cre does increase transposon mobilization. With refinement, this system 
could be used in conjunction with an inducible Cre for temporal control over the 
transposon mutagenesis screens. 
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Figure 6. Excision assay demonstrating inducible transposon mobilization with injected 
Cre mRNA. Genotypes refer to the presence of transposase/transposon. 
 
Other tissue specific promoters expressed in the brain that were explored include 
gfap and nestin promoters. These promoters have been used as reporters for radial glia 
and stem cells in the brain (Lam et al., 2009). Progress has been made in cloning these 
promoters into several constructs, but transgenic lines have not yet been produced. The 
gfap promoter has been cloned into the pTol2<gfap:SB11, cmlc2:GFP> vector to drive 
SB11 expression. However, there are alternative translation start sites upstream of the 
SB11 coding region that may prevent or hinder SB11 from being successfully translated. 
Before this construct is used to create a transgenic line, these alternative start sites should 
be removed. The nestin promoter was cloned successfully from genomic DNA and 
inserted into a multiple cloning site vector. 
The construction of these plasmids opened up the ability to create another 
transgenic line that would be beneficial in the lab. This construct was modified to drive 
the ubiquitous expression of GFP, which lead to the establishment of the Tg(ubi:GFP) 
line. This transgenic has been used for several experiments involving transplantation. 
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The transgenics expressing transposase sources were designed and constructed in 
this research to catalyze the mobilization of a transposon in two other lines, shown in 
Figure 7. The first is T2/OncZ that has been used in the lab previously (McGrail et al., 
2011). It contains a termination signal to stop transcription if integrated within a gene, 
and a β-actin promoter to drive overexpression of a downstream gene. The other 
transposon that will be used is T2/OncZgb1. It has the additional advantage of tagging 
disrupted proteins with RFP when inserted in the correct reading frame. Both of the lines 
were previously created in the lab by injecting linear DNA into zebrafish embryos. The 
linear DNA formed a concatemer consisting of many copies of the transposon, and this 
transposon array was inserted randomly into the genome. In this research, the T2/OncZ 
transposon line will primarily be used at a small scale to test transposase sources, while 
the T2/OncZgb1 transposon will be used for the large scale mutagenesis screens. 
 
Figure 7. Schematic of the two transposon lines that will be used in this study. 
 
Mapping common integration sites of the T2OncZgb1 transposon following mobilization 
Common integration sites are being mapped following the mobilization of the 
T2OncZgb1 transposon by the Tg(β-actin:SB11) transgenic line. This will identify 
integration hotspots in the genome, which will allow these sites to be removed as 
background when analyzing the data from somatic mutagenesis screens. At 2 months of 
age, the double transgenics were sacrificed and genomic DNA was extracted for library 
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preparation. In total, 48 individual fish produced libraries for the right and left transposon 
arms. Each library was prepared with a barcoded primer that would allow multiplexing 
during sequencing. 
In order to verify that the constructed libraries contained fragments of genomic 
DNA surrounding the transposon insertion site, several random amplified products were 
cloned and sequenced using standard sequencing. The results revealed that most of the 
samples contained transposon concatemer sequence, instead of mapping to the genome. 
However, these segments were flanked by the sequencing and linker primers used to 
construct the libraries. In addition, the barcode sequence corresponding to the library 
sample was recovered. This suggested that the library construction was successful and 
ready for next generation sequencing. 
The MiSeq has been performed for the first 24 samples of the left arm of the 
transposon. Sequencing returned a total of 18.3 million reads. 17.3 million reads 
remained after removing sequences that did not have the TA dinucleotide requirement for 
integration. A large percentage of the read mapped to the transposon itself, and only 2% 
of the read mapped to the genome. This indicates that the libraries contain a significant 
amount of intact transposon, pointing to an incomplete secondary digestion. Analysis is 
still ongoing, but a few common integration plots have been constructed for one barcoded 
sample, which are shown in Figure 8. In particular, there appears to be a common 
integration site on chromosome 3 at the β-actin promoter. This was observed previously 
as well (McGrail et al., 2011). The process of mapping the reads to the zebrafish genome 
will identify common integration sites, and is currently underway. 
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Figure 8. Preliminary analysis of common integration sites showing 
increased integration at the β-actin promoter on chromosome 3. 
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Genome wide mutagenesis in to screen for tumor suppressors and oncogenes 
 Transposon mutagenesis screens were targeted to neural progenitors using the 
described transgenic lines. Four separate screens are currently being monitored in the lab, 
including two screens using the T2/OncZ transposon line and two with the T2/OncZgb1 
transposon line. The first screen using the Tg(krt5:SB11) transgenic was with the 
T2/OncZ transposon line. A second screen using this cross was setup to examine changes 
in tumorigenesis in the pRB deficient background by injecting CRISPRs into single-cell 
stage embryos. However, analysis showed that there was no mutagenesis at the rb1 locus. 
As a result, these fish were raised as a wild type background. These screens are 
summarized in Table 6. Of this second screen, one individual out of 10 showed tumor 
formation. Performing the excision assay in Figure 9, it was shown that transposon 
mobilization was detected in the tumor tissue, but not in the control muscle tissue. This 
indicates that the Tg(krt5:SB11) transgenic can induce tumorigenesis by mobilization of 
the transposon in specific tissues. Due to the limited numbers of fish involved in this 
screen, the significance of these results can not be established. 
 
Table 6. The number of adult fish of each genotype 
from crosses between Tg(krt5:SB11) and T2/OncZ. 
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Figure 9. Excision assay showing transposon 
mobilization specifically in tumorous tissue. 
 
 A similar large scale screen is also being monitored using the T2/OncZgb1 
transposon line. Transposon mobilization was again confirmed in double transgenics 
using an excision assay of larvae. In addition, an excision assay performed on dissected 
brains of adult individuals showed transposon mobilization in the presence of the 
transposase in the Tg(krt5:SB11) transgenic. Lastly, the other screen in progress was done 
in the pRB deficient background. This was achieved by targeting rb1 with TALENs to 
create mosaic mutants that are known to give raise to tumorigenesis. These screens are 
summarized in Table 7. 
 
Table 7. The number of adult fish of each genotype from crosses between 
Tg(krt5:SB11) and T2/OncZ in wild type and pRB deficient backgrounds. 
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Discussion 
The purpose of this research was to utilize transposon somatic mutagenesis to 
gain a better understanding of brain tumorigenesis. Significant progress has been made in 
the development of transgenic zebrafish lines to drive transposon mutagenesis in a tissue-
specific and inducible manner. The most important has been the Tg(krt5:SB11) transgenic 
line, which targets mutagenesis to neural progenitors. The functionality of this line has 
been demonstrated through excision assays showing this transposase source can mobilize 
the T2/OncZ and T2/OncZgb1 transposons. Several mutagenesis screens are currently 
being monitored in the lab that uses this transgenic line. One of these screens resulted in 
tumor induction in the brain, with further analysis indicating transposon mobilization was 
achieved in the tumor, but not in control tissue. This is an important proof of concept that 
justifies the large scale screens. A screen is also being conducted in the pRB deficient 
mutant, a tumor susceptible background. To date, the number of fish exhibiting tumor 
induction in the mutagenesis screens has not been sufficient to establish statistical 
meaning. If a significant number of fish do not develop tumors, it may be necessary to 
make modifications to increase the rate of tumorigenesis. One option would be to repeat 
the screen in a pRB deficient background in combination with p53 mutants.  
One of the most important pieces of data still needed is the characterization of the 
expression pattern of the Tg(krt5:SB11) transgenic. Since the results of the in situ 
hybridization were inconclusive, the experiment needs to be repeated with a redesigned 
probe. A shorter probe consisting of several hundred base pairs would not have homology 
with the zebrafish genome, and would likely yield better results. 
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 The inducible Tg(ubi:floxed-SB11) transposase source has also been generated 
and tested. It was shown that the transgenic line could increase transposon mobilization 
with Cre recombinase. However, there was a small amount of SB11 expression that is 
ubiquitous, suggesting the 2xSV40 transcription terminator that was used is leaky. 
Refinements to this system could include replacing the 2xSV40 with a stronger 
terminator. This modification would be required to make this a viable method for an 
inducible transposon mutagenesis system. 
The construction of the libraries for the common integration site analysis is 
completed, and the data is currently being analyzed. The results should show hotspots for 
transposon integration, as well as local hopping around the location of the transposon 
concatemer. This data will be beneficial when analyzing the mapping results from the 
mutagenesis screens. 
In the course of this research, several molecular tools and transgenic zebrafish 
lines have been generated for transposon mutagenesis. It is known that cancer results 
from a complex interaction of several factors. These transposon mutagenesis screens will 
therefore be important to identify cooperative genes that affect tumorigenesis in the brain. 
Discovering the genetic mechanisms that drive proliferation of neural progenitors will 
provide insights into possible treatment of brain cancers, including PNETs. A more 
complete understanding of the genetic landscape of PNETs will lead to new treatments 
that will have a positive impact on human lives. 
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APPENDIX 
QUANTIFYING DIFFERENTIAL GENE EXPRESSION IN AN 
OPTIC PATHWAY TUMOR LINE 
 
 In a previous study, the lab characterized the transgenic zebrafish line 
Tg(flk1:RFP)is18, which developed tumors in the optic pathway (Solin et al., 2014). 
These tumors exhibited properties of retinoblastoma and fibrous glioma. It was 
determined that the tumors were caused by the disruption of a long, intergenic non-
coding RNA gene lincRNAis18. A part of the characterization of this mutant line was 
transcriptome analysis of pre-tumor and tumor retina using RNAseq. The purpose of my 
experiments in this study was to validate the RNAseq data for several key genes using 
quantitative PCR in order to measure differences in gene expression. These genes 
included ajap1, ascl1a, atf3, bysl, hbegfa, and insm1a.  
 Primers were designed for each gene of interest to amplify 100-110 bp amplicon. 
Table 8 provides the primer sequences. A standard curve for each primer pair was 
constructed to test for primer efficiency and determine any off target amplification. This 
was achieved through a 1 to 10000 dilution of control cDNA. A two-step qRT-PCR was 
performed using SYBR green master mix. Each reaction was performed in triplicate. 
Template consisted of 50 ng of control, pre-tumor, and tumor cDNA samples. cDNA was 
reverse transcribed from tissue samples using oligo-dT primers and the Invitrogen 
SuperScript III kit. qRT-PCR was performed on the LightCycler instrument. Fold change 
was calculated using β-actin as an endogenous control. 
27 
 
The differential gene expression measured using qRT-PCR was similar to the 
RNAseq results, as shown in Figure 10. In most cases, a greater increase in gene 
expression was observed. In particular, ascl1a and hbegfa showed a much higher fold 
change than was detected using RNAseq. The results show that the tumor suppressor 
ajap1 was significantly decreased in the tumor. The increase expression of atf3, which 
encodes a cAMP-response element binding protein, suggests that cAMP signaling plays a 
role in tumor growth. The constant expression of bysl throughout the samples ruled out 
optic nerve injury as the cause for this upregulation of atf3. In addition, the tumors 
showed a significant increase in gene expression for several activators of wnt-β-cantenin 
signaling in glial progenitors, including hbegfa, ascl1a, and insm1a. This analysis 
supports the hypothesis that Tg(flk1:RFP)is18 retinal tumors result from Müller glia that 
dedifferentiate to give raise to transformed neuroglial progenitors. 
 
  
Figure 10. Differential gene expression measured 
by qRT-PCR and compared to RNAseq. 
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Table 8. List of primers used in the qRT-PCR analysis. 
 
Primer Name Sequence (5’ to 3’) 
RT_ajap1_F GATCATCACCATCACTGTGTCC 
RT_ajap1_R TTTCTCTGATGGCTGCTGTG 
RT_ascl1a_F ATGAACTCTATGGCCGGTTC 
RT_ascl1a_R TAAGTTTCCTTTTACGAACGCTC 
RT_atf3_F CAGCAGCAAAATGTCGGAAC 
RT_atf3_R GCTGCTTTTGGTTCTTCAGC 
RT_bactin_F CGAGCTGTCTTCCCATCCA 
RT_bactin_R TCACCAACGTAGCTGTCTTTCTG 
RT_bysl_F CTTCTACAATCTGGTGCTGCTG 
RT_bysl_R GAGCAGGATCCCTTTGAACC 
RT_hbegfa_F ATTTCTCTCTGCCGGTGAAG 
RT_hbegfa_R TGCTTGTGAAACCTGAGTGC 
RT_insm1a_F AGGTCTACCCGTGCAAATACTG 
RT_insm1a_R GGCATCTGAAGCAGGATCAC 
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